Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Conditions: HER2-positive Breast Cancer; HER2 Gene Mutation; HER-2 Gene Amplification; HER2 Positive Gastric Cancer; Salivary Gland Cancer; Salivary Gland Tumor; Salivary Gland Carcinoma; Salivary Gland Neoplasms; Lung Cancer; Colo-rectal Cancer; Rare Diseases; Solid Tumor; Recurrent Gastric Cancer; Recurrent Colon Cancer; Recurrent Breast Cancer; Head and Neck Cancer; Head and Neck Carcinoma; Bladder Cancer; Cervical Cancer; Liver Cancer; Bile Duct Cancer; Urologic Cancer; Pancreatic Cancer; Prostate Cancer; Recurrent Prostate Cancer; Rectal Cancer; Recurrent Ovarian Carcinoma; Recurrent Renal Cell Cancer; Rectal Cancer Stage II; Rectal Cancer Stage I; Rectal Cancer Stage III; Skin Cancer; Mouth Cancer; Lip Cancer Stage I; Tongue Cancer; Breast Neoplasm Malignant Primary; Larynx Cancer; Tonsil Cancer; Palate Cancer; Mucoepidermoid Carcinoma; Primary Peritoneal Carcinoma; Mucinous Adenocarcinoma Gastric; Mucinous Breast Cancer Recurrent; Cholangiocarcinoma
Intervention: Drug: A166
Sponsor: Klus Pharma Inc.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.